Trifecta Pharmaceuticals recalled 14,700 bottles of Globe Clotrimazole Cream USP on October 31, 2025, due to significant cGMP deviations. The affected product may not meet necessary safety and quality standards. Consumers should stop using the cream immediately and seek guidance from healthcare providers.
cGMP deviations
Consumers and healthcare providers should stop using this product immediately. Contact Blossom Pharmaceuticals or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves Globe Clotrimazole Cream USP, 1% antifungal cream, packaged in 5 oz. (142 g) tubes. The affected lot number is A472418. The product was distributed nationwide in the USA.
The recall stems from deviations in current Good Manufacturing Practice (cGMP) regulations. These violations can lead to products that are not safe or effective, posing potential health risks.
Currently, there are no reported injuries or adverse effects linked to the use of this product. However, the potential for harm exists due to the manufacturing deficiencies.
Consumers should stop using the product immediately. For further guidance, contact Blossom Pharmaceuticals or consult with a healthcare provider.
For inquiries regarding the recall, consumers can reach Trifecta Pharmaceuticals at their office located at 101 NE Third Avenue, Suite 1500, Ft. Lauderdale, FL 33301, USA.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.